Suppr超能文献

[第三届全国卵巢共识。2011年。墨西哥卵巢癌和妇科肿瘤研究小组“GICOM”]

[Third National Ovarian Consensus. 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"].

作者信息

Gallardo-Rincón Dolores, Cantú-de-León David, Alanís-López Patricia, Alvarez-Avitia Miguel Angel, Bañuelos-Flores Joel, Herbert-Núñez Guillermo Sidney, Oñate-Ocaña Luis Fernando, Pérez-Montiel María Delia, Rodríguez-Trejo Amelia, Ruvalcaba-Limón Eva, Serrano-Olvera Alberto, Ortega-Rojo Andrea, Cortés-Esteban Patricia, Erazo-Valle Aura, Gerson-Cwilich Raquel, De-la-Garza-Salazar Jaime, Green-Renner Dan, León-Rodríguez Eucario, Morales-Vásquez Flavia, Poveda-Velasco Andrés, Aguilar-Ponce José Luis, Alva-López Luis Felipe, Alvarado-Aguilar Salvador, Alvarado-Cabrero Isabel, Aquino-Mendoza Cinthia Alejandra, Aranda-Flores Carlos Eduardo, Bandera-Delgado Artfy, Barragán-Curiel Eduardo, Barrón-Rodríguez Patricia, Brom-Valladares Rocío, Cabrera-Galeana Paula Anel, Calderillo-Ruiz Germán, Camacho-Gutiérrez Salvador, Capdeville-García Daniel, Cárdenas-Sánchez Jesús, Carlón-Zárate Elisa, Carrillo-Garibaldi Oscar, Castorena-Roji Gerardo, Cervantes-Sánchez Guadalupe, Coronel-Martínez Jaime Alberto, Chanona-Vilchis José Gregorio, Díaz-Hernández Verónica, Escudero-de-los Ríos Pedro, Garibay-Cerdenares Olga, Gómez-García Eva, Herrera-Montalvo Luis Alonso, Hinojosa-García Luz María, Isla-Ortiz David, Jiménez-López Josefina, Lavín-Lozano Arturo Javier, Limón-Rodriguez Jesús Alberto, López-Basave Horacio Noé, López-García Sergio César, Maffuz-Aziz Antonio, Martínez-Cedillo Jorge, Martínez-López Dulce María, Medina-Castro Juan Manuel, Melo-Martínez Carlos, Méndez-Herrera Carmen, Montalvo-Esquivel Gonzalo, Morales-Palomares Miguel Angel, Morán-Mendoza Andrés, Morgan-Villela Gilberto, Mota-García Aída, Muñoz-González David Eduardo, Ochoa-Carrillo Francisco J, Pérez-Amador Maricruz, Recinos-Money Edgar, Rivera-Rivera Samuel, Robles Flores Juan U, Rojas-Castillo Edith, Rojas-Marín Carlos, Salas-Gonzáles Efraín, Sámano-Nateras Liliana, Santibañez-Andrade Miguel, Santillán-Gómez Antonio, Silva-García Araceli, Silva Juan Alejandro, Solorza-Luna Gilberto, Tabarez-Ortiz Adán Raúl, Talamás-Rohana Patricia, Tirado-Gómez Laura Leticia, Torres-Lobatón Alfonso, Quijano-Castro Félix

机构信息

Instituto Nacional de Cancerología, Tlalpan, Mexico.

出版信息

Rev Invest Clin. 2011 Nov-Dec;63(6):665-702.

Abstract

INTRODUCTION

Ovarian cancer (OC) is the third most common gynecologic malignancy worldwide. Most of cases it is of epithelial origin. At the present time there is not a standardized screening method, which makes difficult the early diagnosis. The 5-year survival is 90% for early stages, however most cases present at advanced stages, which have a 5-year survival of only 5-20%. GICOM collaborative group, under the auspice of different institutions, have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia.

MATERIAL AND METHODS

The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of two days in which a debate was held. These statements are the conclusions reached by agreement of the participant members.

RESULTS

No screening method is recommended at the time for the detection of early lesions of ovarian cancer in general population. Staging is surgical, according to FIGO. In regards to the pre-surgery evaluation of the patient, it is recommended to perform chest radiography and CT scan of abdomen and pelvis with IV contrast. According to the histopathology of the tumor, in order to consider it as borderline, the minimum percentage of proliferative component must be 10% of tumor's surface. The recommended standardized treatment includes primary surgery for diagnosis, staging and cytoreduction, followed by adjuvant chemotherapy Surgery must be performed by an Oncologist Gynecologist or an Oncologist Surgeon because inadequate surgery performed by another specialist has been reported in 75% of cases. In regards to surgery it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10-30% of all cases, and systematic limphadenectomy, necessary to be able to obtain an adequate surgical staging. Fertility-sparing surgery will be performed in certain cases, the procedure should include a detailed inspection of the contralateral ovary and also negative for malignancy omentum and ovary biopsy. Until now, laparoscopy for diagnostic-staging surgery is not well known as a recommended method. The recommended chemotherapy is based on platin and taxanes for 6 cycles, except in Stage IA, IB and grade 1, which have a good prognosis. In advanced stages, primary cytoreduction is recommended as initial treatment. Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer. Radiotherapy can be used to palliate symptoms. Follow up of the patients every 2-4 months for 2 years, every 3-6 months for 3 years and anually after the 5th year is recommended. Evaluation of quality of life of the patient must be done periodically.

CONCLUSIONS

In the present, there is not a standardized screening method. Diagnosis in early stages means a better survival. Standardized treatment includes primary surgery with the objective to perform an optimal cytoreduction followed by chemotherapy Treatment must be individualized according to each patient. Radiotherapy can be indicated to palliate symptoms.

摘要

引言

卵巢癌(OC)是全球第三常见的妇科恶性肿瘤。大多数病例起源于上皮组织。目前尚无标准化的筛查方法,这使得早期诊断变得困难。早期阶段的5年生存率为90%,然而大多数病例在晚期才出现,晚期病例的5年生存率仅为5%-20%。GICOM协作组在不同机构的支持下达成了以下共识,以便就该肿瘤的诊断和管理提出建议。

材料与方法

妇科肿瘤学领域的独立专业人士提出了以下建议,问题和陈述基于对文献的全面系统回顾。这是在为期两天的会议背景下进行的,会议期间进行了辩论。这些陈述是与会成员达成一致的结论。

结果

目前不建议对普通人群进行卵巢癌早期病变检测的筛查方法。分期采用手术分期,依据国际妇产科联盟(FIGO)标准。关于患者的术前评估,建议进行胸部X线检查以及腹部和盆腔的CT增强扫描。根据肿瘤的组织病理学,若要将其视为交界性肿瘤,增殖成分的最小百分比必须占肿瘤表面的10%。推荐的标准化治疗包括用于诊断、分期和减瘤的初次手术,随后进行辅助化疗。手术必须由妇科肿瘤学家或肿瘤外科医生进行,因为据报道75%的病例中由其他专科医生进行的手术不充分。关于手术,建议进行全网膜切除术,因为在所有病例中有10%-30%记录有亚临床转移,还建议进行系统性淋巴结清扫,这对于获得充分的手术分期是必要的。在某些情况下将进行保留生育功能的手术,该手术应包括对侧卵巢的详细检查以及大网膜和卵巢的恶性阴性活检。到目前为止,腹腔镜诊断分期手术作为推荐方法并不为人熟知。推荐的化疗方案是以铂类和紫杉类为基础进行6个周期的化疗,但IA期、IB期且1级的病例预后良好除外。在晚期,建议进行初次减瘤作为初始治疗。对于晚期卵巢癌的治疗,不推荐微创外科手术。放疗可用于缓解症状。建议对患者每2-4个月随访2年,每3-6个月随访3年,5年后每年随访。必须定期评估患者的生活质量。

结论

目前尚无标准化的筛查方法。早期诊断意味着更好的生存率。标准化治疗包括以实现最佳减瘤为目标的初次手术,随后进行化疗。治疗必须根据每个患者进行个体化。放疗可用于缓解症状。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验